202 related articles for article (PubMed ID: 34855202)
1. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
2. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
3. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
4. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G; Wen HY
Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
[TBL] [Abstract][Full Text] [Related]
5. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
8. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
[TBL] [Abstract][Full Text] [Related]
10. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
11. Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Mariotto A; Jayasekerea J; Petkov V; Schechter CB; Enewold L; Helzlsouer KJ; Feuer EJ; Mandelblatt JS
J Natl Cancer Inst; 2020 Feb; 112(2):154-160. PubMed ID: 31165854
[TBL] [Abstract][Full Text] [Related]
12. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
[TBL] [Abstract][Full Text] [Related]
13. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
[TBL] [Abstract][Full Text] [Related]
14. Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx.
Chiru ED; Oseledchyk A; Schoetzau A; Kurzeder C; Mosimann R; Vetter M; Grašič Kuhar C
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201405
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
[TBL] [Abstract][Full Text] [Related]
16. Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.
Henderson J; Adams P; Barber K
Clin Breast Cancer; 2019 Jun; 19(3):e475-e480. PubMed ID: 30852142
[TBL] [Abstract][Full Text] [Related]
17. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
18. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
19. 21-Gene Recurrence Score Testing in HER2-positive Patients.
Altman AM; Marmor S; Tuttle TM; Hui JYC
Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
[TBL] [Abstract][Full Text] [Related]
20. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
